期刊文献+

奥沙利铂加卡培他滨治疗晚期直肠癌的疗效观察 被引量:2

Clinical Observation on Advanced Rectal Cancer on the Treatment of Oxaliplatin Combined with Capecitabine
下载PDF
导出
摘要 目的总结奥沙利铂+卡培他滨治疗晚期结直肠癌的疗效。方法对照组给予奥沙利铂联合5-FU治疗,即选择5%葡萄糖500mL实施静脉滴注,同时选择奥沙利铂130mg/m2、5-FU500mg/m2实施静脉滴注,时间约为2h,需持续使用5d,化疗周期为21d;治疗组给予奥沙利铂联合卡培他滨治疗,即选择5%葡萄糖500mL、奥沙利铂130mg/m2实施静脉滴注,时间为2h,同时选择卡培他滨2500mg/m2,每天服用2次,需持续使用2个星期,化疗前半个小时使用5-羟色氨酸受体阻断剂,避免消化道出现不良反应,化疗周期为21d。结果对照组总有效率为55.56%,治疗组总有效率为78.57%,两组差异存在统计学意义(P<0.05);对照组不良反应14例,不良反应发生率为51.85%,治疗组不良反应13例,不良反应发生率为46.43%,两组不良反应发生率差异不明显,无统计学意义(P>0.05)。结论奥沙利铂+卡培他滨治疗晚期结直肠癌,可取得较好的疗效,值得在临床医学中推广使用。 Objectives To summarize the clinical effect of oxaliplatin combined with capecitabine to treat advanced rectal cancer.Methods The control group was treated with oxaliplatin,selecting 500mL of 5% glucose and 130mg/m2 of oxaliplatin to implement intravenous infusion,the time was about 2h.The treatment group were given the treatment of oxaliplatin combined with capecitabine,choosing 500mL of 5% glucose and 130mg/m2 of oxaliplatin to implement intravenous infusion,the time was about 2h,at the same time selecting 2500mg/m2 of capecitabine,which should be taken 2 times everyday and need to be continued for two weeks.Applying 5-oxitriptan receptor blocking agent half an hour before chemotherapy to avoid gastrointestinal adverse reactions.One treatment course is 20d.Results The total effective rate of the control group and the treatment group was 55.56% and 78.57%.There was statistical significance between 2 groups(P0.05).As for the control group,there were 14 cases of adverse drug reactions and the incidence of adverse reactions was 51.85%.There were 13 cases of adverse drug reactions in the treatment group and the incidence of adverse reactions was 46.43%.There was no evident difference for the incidence of adverse reactions between 2 groups,which had no statistical significance(P0.05).Conclusions Oxaliplatin combined with capecitabine to treat advanced rectal cancer can get better clinical effect,which is worthy to be promoted and applied in clinical medicine.
作者 黄宪平
出处 《中国医药指南》 2012年第35期411-412,共2页 Guide of China Medicine
关键词 奥沙利铂 卡培他滨 晚期结直肠癌 治疗 疗效 Oxaliplatin Capecitabine Advanced rectal cancer Treatment Clinical effect
  • 相关文献

参考文献5

二级参考文献48

  • 1张文,赵子仪,吴晴,陈嘉,徐农,吴昌平,李进,许立功.改良FOLFIRI方案用于奥沙利铂和氟尿嘧啶类药物治疗失败的晚期结直肠癌临床研究[J].中华肿瘤杂志,2006,28(10):788-790. 被引量:8
  • 2Kim R, Ohi Y, Inoue H, et al .Expression and relationship between topoisomerase Ⅰ and Ⅱ alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers[J]. Anticancer Res, 1999,19(16B) :5 393.
  • 3Bouche O, Raoul JL, Bonnetain F, et al .Randomized multicenter phase Ⅱ trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LVSFU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study- FFCD 9803[J ]. J Clin Oncol,2004,22(21) :4 319.
  • 4Burris HA, Moore M J, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first - time therapy for patients with advanced pancreas cancer: a randomized trial[J] . J Clin Oncol, 1997,15(6) :2 403.
  • 5De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin in as first line treatment in advanced colorectal cancer[J] . J Clin Oncol, 2000,18(16) : 2 938.
  • 6Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J]. J Clin Oncol, 2004, 22(1):23.
  • 7Mabro M, Louvet C, Andrc T, et al. Bimonthly leucovorin, infusion 5- fluorouraeil, hydroxyurea, and irinotecan (FOLFIRI - 2) for pretreated metastatic colorectal cancer[J] . Am J Clin Oncol( CCT) , 2003, 26(3) ~ 254.
  • 8McGavin JK, Goa KL.Capecitabine: a review of its use in the treament of advanced or metastatic colorectal cancer[J ]. Drugs, 2001,61(15) : 2 309.
  • 9Hoff PM, Ansari R, Batist G, et al .Comparison of oral eapecitabine versus intravenous fluorouracil plus leucovorin as first- line treatment in 605 patients with metastatic coloreetal cancer: results of a randomized phase Ⅲ study[J ]. J Clin Oncol, 2001,19(8) :2 282.
  • 10Cassidy J, Twelves C, Van Cutsem E, et al. First - line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5- fluorluracil/ leucovorin[J] . Ann Oncol, 2002,13(4) : 566.

共引文献19

同被引文献11

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部